By Donna Loyle, communications manager, LIMR
Researchers, including those at MLH, seek to evaluate the performance of fludeoxyglucose F-18 (FDG)-PET/CT response criteria as a binary predictor of progression-free survival in patients with bone-dominant metastatic breast cancer treated with systemic therapy.
Participants in this phase II, non-randomized clinical trial receive FDG intravenous solution and undergo PET/CT scan over 15 to 30 minutes within 21 days before start of standard treatment, and then again at 12 weeks after start of standard treatment.
- Must have been diagnosed with metastatic breast cancer that is hormone-receptor positive and with known HER2 status and whose cancer has spread only or predominantly to the bones
- Must be able to undergo FDG-PET imaging
- Must be undergoing a systemic therapy such as endocrine therapy, chemotherapy or an HER2-targeted treatment
- Other inclusion and exclusion criteria apply
Study #EA1183 is approved for all MLH acute care hospitals. The principal investigator is Paul Gilman, MD. For more, email firstname.lastname@example.org or visit https://www.mainlinehealth.org/research/clinical-trials/ea1183.